Left Atrial Appendage Occlusion for Stroke Prevention

Oluseun O. Alli; David R. Holmes

doi:10.1016/j.cpcardiol.2015.06.005

Left Atrial Appendage Occlusion for Stroke Prevention

Oluseun O. Alli, David R. Holmes

Cardiovascular Medicine

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Atrial fibrillation (AF) remains the most common arrhythmia encountered in clinical practice. One of its more common deleterious effects is the development of thromboembolism leading to stroke. The left atrial appendage (LAA) has been shown to the site of the majority of thrombus formation leading to stroke. Anticoagulation with warfarin has been the treatment of choice for prevention of embolic events. Newer anticoagulants have been developed but they still have the potential side effect of causing major bleeding. Occlusion of the LAA has emerged as an alternative therapeutic approach to medical therapy. The aim of this article is to discuss in detail the role of the LAA in thromboembolism in AF, role of device and surgical therapies, and the current clinical data supporting their use. This is particularly timely in that there is now an approved LAA closure device approved in the US for stroke prevention in patients with nonvalvular AF.

Original language	English (US)
Pages (from-to)	429-476
Number of pages	48
Journal	Current Problems in Cardiology
Volume	40
Issue number	10
DOIs	https://doi.org/10.1016/j.cpcardiol.2015.06.005
State	Published - Oct 1 2015

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.cpcardiol.2015.06.005

Cite this

@article{cb4d272ca14b4312a24466e4cbe880c2,

title = "Left Atrial Appendage Occlusion for Stroke Prevention",

abstract = "Atrial fibrillation (AF) remains the most common arrhythmia encountered in clinical practice. One of its more common deleterious effects is the development of thromboembolism leading to stroke. The left atrial appendage (LAA) has been shown to the site of the majority of thrombus formation leading to stroke. Anticoagulation with warfarin has been the treatment of choice for prevention of embolic events. Newer anticoagulants have been developed but they still have the potential side effect of causing major bleeding. Occlusion of the LAA has emerged as an alternative therapeutic approach to medical therapy. The aim of this article is to discuss in detail the role of the LAA in thromboembolism in AF, role of device and surgical therapies, and the current clinical data supporting their use. This is particularly timely in that there is now an approved LAA closure device approved in the US for stroke prevention in patients with nonvalvular AF.",

author = "Alli, {Oluseun O.} and Holmes, {David R.}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = oct,

day = "1",

doi = "10.1016/j.cpcardiol.2015.06.005",

language = "English (US)",

volume = "40",

pages = "429--476",

journal = "Current Problems in Cardiology",

issn = "0146-2806",

publisher = "Mosby Inc.",

number = "10",

}

TY - JOUR

T1 - Left Atrial Appendage Occlusion for Stroke Prevention

AU - Alli, Oluseun O.

AU - Holmes, David R.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Atrial fibrillation (AF) remains the most common arrhythmia encountered in clinical practice. One of its more common deleterious effects is the development of thromboembolism leading to stroke. The left atrial appendage (LAA) has been shown to the site of the majority of thrombus formation leading to stroke. Anticoagulation with warfarin has been the treatment of choice for prevention of embolic events. Newer anticoagulants have been developed but they still have the potential side effect of causing major bleeding. Occlusion of the LAA has emerged as an alternative therapeutic approach to medical therapy. The aim of this article is to discuss in detail the role of the LAA in thromboembolism in AF, role of device and surgical therapies, and the current clinical data supporting their use. This is particularly timely in that there is now an approved LAA closure device approved in the US for stroke prevention in patients with nonvalvular AF.

AB - Atrial fibrillation (AF) remains the most common arrhythmia encountered in clinical practice. One of its more common deleterious effects is the development of thromboembolism leading to stroke. The left atrial appendage (LAA) has been shown to the site of the majority of thrombus formation leading to stroke. Anticoagulation with warfarin has been the treatment of choice for prevention of embolic events. Newer anticoagulants have been developed but they still have the potential side effect of causing major bleeding. Occlusion of the LAA has emerged as an alternative therapeutic approach to medical therapy. The aim of this article is to discuss in detail the role of the LAA in thromboembolism in AF, role of device and surgical therapies, and the current clinical data supporting their use. This is particularly timely in that there is now an approved LAA closure device approved in the US for stroke prevention in patients with nonvalvular AF.

UR - http://www.scopus.com/inward/record.url?scp=84942552377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942552377&partnerID=8YFLogxK

U2 - 10.1016/j.cpcardiol.2015.06.005

DO - 10.1016/j.cpcardiol.2015.06.005

M3 - Article

C2 - 26382881

AN - SCOPUS:84942552377

SN - 0146-2806

VL - 40

SP - 429

EP - 476

JO - Current Problems in Cardiology

JF - Current Problems in Cardiology

IS - 10

ER -

Left Atrial Appendage Occlusion for Stroke Prevention

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this